Lead Product(s): SJX-653
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
The Phase 2 clinical trial is a 12-week, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of SJX-653 in reducing vasomotor symptoms.